Reporter Seongmin Kim, Bio Spectator
This article ‘Premium News Service BioS+’ Article.
CITYSCAPE Phase 2 clinical results based on results of improvement in ORR and PFS in patients with high PD-L1 expression
Can Roche be a leader in the PD-(L)1 immunotherapy market? The combined administration of TIGIT antibody and PD-L1, which Roche is promoting as a core development strategy, has been designated as a breakthrough therapy designation by the US Food and Drug Administration (FDA). Roche is one of the leading companies in the development of TIGIT immune anticancer drugs, and it has taken a step further after it first announced the clinical results of co-administration of TIGIT and PD-L1 drugs last year.
Roche is the first-line treatment for non-small cell lung cancer with high expression of PD-L1 without EGFR or ALK mutation from the FDA on the 5th (local time). TIGIT antibody’tiragolumab’ and PD-L1 antibody’Tecentriq®, atezolizumab)’ has been designated as an innovative treatment for combination therapy.
“We are a’chemotherapy-free combination’ across many early carcinomas with high unmet need,” said Levi Garraway, Roche’s Global Head of Clinical Development. “We will advance the tiragolumab clinical program.”
The designation of an innovative treatment by the FDA is based on the results of the Phase 2 clinical trial of CITYSCAPE in which tiragolumab and Tisentic were co-administered for PD-L1-positive metastatic non-small cell lung cancer….
Additional content is available only to paid members.
If you are a member, please log in and click to register as a member.